Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib with or without Apatinib in Metastatic Castration-resistant Prostate Cancer
CTR20210944Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui Therapeutics. Started Apr 2021; status: completed.
02
Drugs
fluzoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20210944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210944.